Vertex Pharmaceuticals Incorporated (LON:0QZU)

Market Cap	81.85B
Revenue (ttm)	8.72B
Net Income (ttm)	2.73B
Shares Out	n/a
EPS (ttm)	10.58
PE Ratio	29.94
Forward PE	20.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	565
Average Volume	631
Open	418.67
Previous Close	421.33
Day's Range	416.89 - 430.45
52-Week Range	362.50 - 519.68
Beta	0.32
RSI	56.18
Earnings Date	Nov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QZU

Financial Performance

Financial numbers in USD